FLIR Systems Announces Four New Exx-Series Handheld Thermal Imaging Cameras
FLIR Systems, Inc. (NASDAQ: FLIR) today announced four new additions to its Exx-Series of advanced thermal imaging cameras: the E96, E86, E76 and E54. Compared to predecessor Exx-Series cameras, the new cameras offer enhanced thermal resolution for more vibrant, easy-to-read images and on-camera routing capability to improve field survey efficiency. The new Exx-Series cameras are designed to help professionals detect the early signs of building issues, identify hot spots, troubleshoot electrical and mechanical systems, and prevent problems before they cause damage that leads to expensive repairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005252/en/
The FLIR E96 camera with on-camera routing capability, combined with FLIR Thermal Studio Pro software is used to identify mechanical issues on a factory floor. (Photo: Business Wire)
The E96, with a 640x480 resolution and eight-times digital zoom, is the most advanced Exx-Series thermal camera to date. It delivers improved measurement results over the greatest distance to target, so professionals can safely diagnose electrical faults or locate hidden anomalies at very high temperatures up to 1500 degrees Celsius (2732 degrees Fahrenheit), including in harsh industrial environments such as steel mills or kilns, to help keep the workplace running smoothly.
For the first time, FLIR Inspection Route is now offered as a standard feature on every Exx-Series camera and is complemented by the FLIR Thermal Studio Pro software with Route Creator plugin, sold separately as an annual subscription. The complete routing bundle enables professionals to create and export custom inspection and pre-planned routes, ideal for large or multi-location electrical or mechanical projects.
“The new Exx-Series advanced thermal imaging cameras enable building professionals, inspectors, engineers, researchers, and facility maintenance personnel to do more than ever before with a handheld thermal camera,” said Rickard Lindvall, General Manager, Solutions Business at FLIR. “With improved thermal resolution and on-camera routing capabilities, the Exx Series can help our customers make better, informed decisions to complete the job more efficiently and effectively.”
The E96, E86, and E76 include UltraMax® high-definition image enhancement technology and improved contrast with one-touch level and spanning functions to view greater image details. In addition, interchangeable AutoCal™ lenses offer complete coverage of near and distance targets, with the built-in laser distance meter ensuring the crisp focus needed for accurate temperature measurement.
The new Exx-Series cameras are available globally starting today through authorized dealers and FLIR.com. To learn more about FLIR Systems’ entire Exx-Series line, visit: www.flir.com/exx-series.
Through March 31, 2021, customers who purchase an Exx-Series camera will receive a free three-month Thermal Studio Pro and Route Creator trial bundle. The FLIR Thermal Studio Suite is also available separately through an annual subscription in Standard and Pro versions, while the Starter version is offered at no charge. To learn more about FLIR Thermal Studio Suite, visit www.flir.com/thermal-studio-suite.
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005252/en/
Contact information
Media Relations:
Eleana Stayer
Phone: +44 7545 204375.
Email: eleana.stayer@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: Investors@flir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom